Poster Presentations Session III
Poster Presentations Session III Tuesday, 1 November 2016
POSTERS SET-UP: 8:30 - 8:45
POSTERS DISPLAY HOURS: 8:45 - 13:45
POSTER AUTHOR DISCUSSION: 12:45 - 13:45
POSTERS DISMANTLE: 13:45


Poster display locations are shown below the poster codes
MENTAL HEALTH - Clinical Outcomes Studies
PMH1
A1
ANTIPSYCHOTIC DRUG PRESCRIBING, COST OF TREATMENT, ADVERSE DRUG REACTION MONITORING, AND QUALITY OF LIFE ASSESSMENT IN OUTPATIENTS OF A TERTIARY CARE HOSPITAL IN DELHI
Kumar S, Chawla S
Maulana Azad Medical College, University of Delhi, New Delhi, India

PMH2
A2
ADVERSE EVENTS IN RELAXING VIRTUAL ENVIRONMENTS
Riedl D1, Loth FL1, Holzner B2, Rumpold G1, Giesinger JM1
1Medical University of Innsbruck, Innsbruck, Austria, 2Medical University of Innsbruck, Department of Psychiatry and Psychotherapy, Innsbruck, Austria

PMH3
A3
RHEUMATOID ARTHRITIS IS ASSOCIATED WITH AN INCREASED RISK OF DEPRESSION IN ELDERLY PATIENTS IN GERMANY
Drosselmeyer J1, Booker A2, Jacob L3, Kostev K2
1Fresenius University, Idstein, Germany, 2IMS Health, Frankfurt am Main, Germany, 3Ecole Normale Superieure of Lyon, Lyon, France

PMH4
A4
Cost-effectiveness of therapist-guided Internet-delivered Cognitive Behavior Therapy for pediatric Obsessive-Compulsive Disorder
Lenhard F1, Ssegonja R2, Andersson E1, Feldman I2, Rück C1, Mataix-Cols D1, Serlachius E1
1Karolinska Institutet, Stockholm, Sweden, 2Uppsala University, Uppsala, Sweden

PMH5
A5
A NETWORK META-ANALYSIS OF ATOMOXETINE, METHYLPHENIDATE, LISDEXAMFETAMINE, AND BUPROPION FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS
Locatelli I, Venišnik K
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PMH6
A6
SYSTEMATIC REVIEW AND META-ANALYSIS OF RISPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA
Hyderboini RK, Vsn M, Inuganti B, Singuru S, Thode R, Sharma S, Likhar N, Dang A
MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, India

PMH7
A7
COST-EFFECTIVENESS OF ACUPUNCTURE TREATMENT IN MENTAL DISORDER: A SYSTEMATIC REVIEW
Kim J1, Kim B2, Kim H3, Jung IC4, Shin S5
1Korea Istitute of Oriental Medicine, Daejeon, South Korea, 2Dongeui University, Pusan, South Korea, 3Semyung University, Jecheon, South Korea, 4Daejeon University, Daejeon, South Korea, 5National Evidence based Health-care Collaborating Agency, Seoul, South Korea

PMH8
A8
QUETIAPINE OFF-LABEL USE
Levin R, Cosmatos I, Dieck G, Reifsnyder J
United BioSource Corporation, Blue Bell, PA, USA

PMH9
A9
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE PREVALENCE AND COMPLICATIONS OF PARAPHENYLENE DIAMINE (PPD) CONTAINING HAIR DYE POISONING IN DEVELOPING COUNTRIES
Bhagavathula AS
University of Gondar, Gondar, Ethiopia

MENTAL HEALTH - Cost Studies
PMH10
A10
BUDGETARY IMPACT ANALYSIS OF REIMBURSEMENT VARENICLINE IN THE SMOKING CESSATION TREATMENT OF PATIENTS WITH MAJOR DEPRESSION IN SPAIN
Cedillo S, Rejas J
Pfizer, Alcobendas, Spain

PMH11
A11
ADVANCED THERAPY MEDICINAL PRODUCTS FOR ALZHEIMER'S DISEASE WILL SHRINK THE NATIONAL HEALTH SERVICE BUDGET
Hanna E1, Zhou J2, Cheng X3, Dorey J4, Aballéa S4, Auquier P1, Toumi M1
1Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France, 2Creativ-Ceutical, Beijing, China, 3Creativ-Ceutical, Hong Kong, Hong Kong, 4Creativ-Ceutical, Paris, France

PMH12
A12
ECONOMIC BURDEN OF SCHIZOPHRENIA IN ITALY: A PROBABILISTIC COST OF ILLNESS ANALYSIS
Marcellusi A1, Fabiano G2, Viti R2, Francesa Morel PC3, Nicolò G4, Siracusano A5, Mennini FS6
1National Research Council (CNR), Rome, Italy, 2Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 3Janssen-Cilag Spa, Colonio Monzese, Italy, 4Asl Roma 5, Colleferro, Italy, 5University of Rome "Tor Vergata", Roma, Italy, 6University of Rome Tor Vergata, Rome, Italy

PMH13
A13
EFFECT OF SMOKING STATUS ON COSTS-OF-ILLNESS IN PATIENTS WITH A DEPRESSIVE DISORDER IN SPAIN: AN APPROXIMATION FROM THE NATIONAL HEALTH SURVEY
Cedillo S, Rejas J
Pfizer, Alcobendas, Spain

PMH14
A14
THE SOCIAL COST OF MAJOR DEPRESSION
Coretti S, Izzo G, Cicchetti A
Università Cattolica del Sacro Cuore, Rome, Italy

PMH15
A15
INPATIENT COSTS OF AGITATION AND CONTAINMENT IN AN URBAN AREA
Serrano-Blanco A1, Rubio-Valera M2, Aznar I2, Baladón L3, Gibert K4, Gracia A5, Ortiz JM1, Kaskens L5, Salvador-Carulla L6
1Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain, 2Fundació Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain, 3Parc Sanitari Sant Joan de Déu, Vilanova i la Geltrú, Spain, 4Universitat Politècnica de Catalunya, Barcelona, Spain, 5Ferrer Internacional, Barcelona, Spain, 6University of Sydney, Sydney, Australia

PMH16
A16
EXCESS COSTS OF PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA IN GERMANY - THE APPLICATION OF ENTROPY BALANCING TO MULTIPLE IMPUTED DATASETS
Brettschneider C1, Bleibler F1, Hiller T2, Konnopka A1, Breitbart J2, Margraf J3, Gensichen J2, König H1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Friedrich-Schiller-University, Jena, Germany, 3Ruhr-University Bochum, Bochum, Germany

PMH17
A17
A REAL-WORLD EVALUATION OF THE CLINICAL AND ECONOMIC BURDEN OF UNITED STATES VETERAN PATIENTS WITH POST-TRAUMATIC STRESS DISORDER
Wang L1, Li L1, Zhou X1, Pandya S1, Baser O2
1STATinMED Research, Plano, TX, USA, 2Columbia University and STATinMED Research, New York, NY, USA

PMH18
A18
HEALTH INSURANCE COST OF MENTAL AND BEHAVIOURAL DISORDERS DUE TO PSYCHOACTIVE SUBSTANCE USE IN HUNGARY: A COST OF ILLNESS STUDY
Oberfrank F1, Donka-Verebes É2, Boncz I3
1Institute of Experimental Medicine, Budapest, Hungary, 2Integra Consulting Zrt., Budapest, Hungary, 3University of Pécs, Pécs, Hungary

PMH19
A19
ESTIMATING THE ECONOMIC BURDEN ASSOCIATED WITH THE EARLY STAGES OF PROGRESSION OF ALZHEIMER’S DISEASE IN EUROPE
Lindgren P1, Jönsson L2, Coste F3, Chan E4, Bosshard R4, for the ICTUS/DSA study group .4
1The Swedish Institute for Health Economics (IHE), Lund, Sweden, 2H. Lundbeck A/S, Valby, Denmark, 3H Lundbeck A/S, Valby, Denmark, 4Otsuka Pharmacuetical Europe Ltd, Wexham, UK

PMH20
A20
IMPACT OF COMORBIDITIES ON THE COST OF DEPRESSION DRUG THERAPY IN GENERAL PRACTICES IN GERMANY
Jacob L1, Ehlken B2, Kostev K3
1Ecole Normale Superieure of Lyon, Lyon, France, 2IMS Health GmbH & Co OHG, RWES, Munich, Germany, 3IMS Health, Frankfurt am Main, Germany

PMH21
A21
OUTCOMES PREDICTION USING A GENERALIZED LINEAR MODEL IN A COHORT OF SCHIZOPHRENIC PATIENTS RECEIVING PALIPERIDONE LONG ACTING INJECTABLE TREATMENT IN HONG KONG
Choon WY1, Lee KK2, Wu BC3, Lee VW4, Tomlinson B4, Hu T4, Chung W5, Lee BS6
1Monash University Malaysia, Selangor, Malaysia, 2Monash University Malaysia, Subang Jaya, Malaysia, 3Ministry of Health Singapore, Singapore, Singapore, 4The Chinese University of Hong Kong, Shatin, Hong Kong, 5Tai Po Hospital, Tai Po, Hong Kong, 6Prince of Wales Hospital, Shatin, Hong Kong, Hong Kong, Hong Kong

PMH22
A22
ECONOMIC IMPACT OF DRUG ADDICTION INTERVENTIONS IN ADULT POPULATION: THE PERU CASE
Triulzi I1, Politi M2, Medive F2, Palla I1, Turchetti G1
1Scuola Superiore Sant'Anna, Pisa, Italy, 2Takiwasi Centre for Addiction treatment and Research on Traditional medicines, Tarapoto, Peru

PMH23
A23
ECONOMIC ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY: COST CONSEQUENCES OF AN EARLY LONG-ACTING INJECTABLE ANTIPSYCHOTICS (LAIS) APPROACH
Marcellusi A1, Mennini FS2, Brugnoli R3, Rapinesi C3, Kotzalidis GD3, De Filippis S3, Carrus D3, Ballerini A4, Francomano A5, Ducci G6, DEL Casale A3, Girardi P3
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 2University of Rome Tor Vergata, Rome, Italy, 3University of Rome "La Sapienza", Rome, Italy, 4University of Florence, Florence, Italy, 5University of Palermo, Palermo, Italy, 6DSM ASL Roma 1, Rome, Italy

PMH24
A24
A COST-EFFECTIVENESS ANALYSIS OF DETOXIFICATION AND MAINTENANCE TREATMENT WITH BUPRENORPHINE/NALOXONE COMBINATION IN TURKEY
Hren R
University of Ljubljana, Ljubljana, Slovenia

PMH25
A25
IMPROVING ACCESS TO PSYCHOLOGICAL THERAPIES IN BRITISH SIGN LANGUAGE (BSL): A COST-EFFECTIVENESS ANALYSIS
Shields GE, Rogers KD, Young A, Buck D, Davies LM
The University of Manchester, Manchester, UK

PMH26
A26
COST-EFFECTIVENESS EVALUATION OF VORTIOXETINE IN MAJOR DEPRESSIVE EPISODE IN THE UK SETTING
Evitt L1, Danchenko N2, Atsou K3, Brignone M3, Diamand F4, Campbell R5
1Lundbeck, MILTON KEYNES, UK, 2Lundbeck S.A.S. Paris Fr, EU, Paris, France, 3Lundbeck SAS, Paris, France, 4Lundbeck S.A.S., Paris, France, 5MAPI Group, London, UK

PMH27
A27
COST-EFFECTIVENESS OF TAKE HOME-NALOXONE FOR THE PREVENTION OF FATALITIES FROM HEROIN OVERDOSE IN THE UK
Langham S1, Kenworthy JJ2, Grieve R3, Dunlop W2
1Maverex Ltd, Manchester, UK, 2Mundipharma International Ltd, Cambridge, UK, 3London School of Hygiene & Tropical Medicine, London, UK

PMH28
A28
THREE-MONTHLY LONG-ACTING FORMULATION OF PALIPERIDONE PALMITATE IS A DOMINANT TREATMENT OPTION, COST SAVING WHILE ADDING QALYS, COMPARED TO THE ONE-MONTHLY FORMULATION IN THE TREATMENT OF SCHIZOPHRENIA IN BELGIUM: A COST-UTILITY STUDY
De Moor R1, Malfait B2, Tedouri F3, De Vos C2, van Gils C1
1IMS Health, Zaventem, Belgium, 2Janssen-Cilag NV, Beerse, Belgium, 3Janssen Pharmaceutica NV, Beerse, Belgium

PMH29
A29
THE COST OF COGNITIVE IMPAIRMENT IN PATIENT WITH MAJOR DEPRESSIVE DISORDER
Coretti S1, Izzo G1, Vaggi M2, Bellomo A3, Mencacci C4, Cicchetti A1
1Università Cattolica del Sacro Cuore, Rome, Italy, 2ASL 3 Genovese, Genoa, Italy, 3Università di Foggia, Foggia, Italy, 4A.O. Fatebenefratelli e Oftalmico, Milan, Italy

MENTAL HEALTH - Patient-Reported Outcomes & Patient Preference Studies
PMH30
A30
WITHDRAWN

PMH31
A31
SUBJECT RECOMMENDATIONS FOR IMPROVING THEIR COMPLIANCE IN COMPLETING ELECTRONIC DIARIES IN DEPRESSION CLINICAL TRIALS
Khurana L1, Gary ST1, Otero AV1, Evans C2, Hall C1, Dallabrida SM1
1ERT, Boston, MA, USA, 2Endpoint Outcomes, Boston, MA, USA

PMH32
A32
UTILITY VALUES IN ECONOMIC MODELS FOR TREATMENTS OF SCHIZOPHRENIA
Zhou J1, Millier A1, Aballéa S1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Aix-Marseille University, Marseille, France

PMH33
A33
THE BURDEN OF DEPRESSION IN JAPAN
Yamabe K1, Umareddy I2, Flores NM3
1Takeda Pharmaceutical Company Ltd., Tokyo, Japan, 2Kantar Health, Singapore, Singapore, 3Kantar Health, Foster City, CA, USA

PMH34
A34
DEVELOPING AND TESTING A STATED-PREFERENCE INSTRUMENT TO PRIORITIZE TREATMENT GOALS AMONG PATIENTS WITH RECENT ONSET SCHIZOPHRENIA
Beusterien K1, Chan E2, Such P3, Laird Ad2, Loze J2, Nylander A3, Robinson P2, Bridges JF4
1ORS Health, Washington, DC, USA, 2Otsuka Pharmaceutical Europe Ltd, Wexham, UK, 3H.Lundbeck AS, Copenhagen, Denmark, 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PMH35
A35
PRO INSTRUMENTS FOR MENTAL DISORDERS USED IN STUDIES PUBLISHED SINCE 2005: WHICH DISEASES HAVE HAD THE MOST TOOLS DEVELOPED?
Martin A
Crystallise Ltd., London, UK

MENTAL HEALTH - Health Care Use & Policy Studies
PMH36
A36
HOSPITALIZED PATIENTS WITH SCHIZOPHRENIA IN PORTUGAL: CLINICAL CHARACTERIZATION AND COSTS
Ascenção R1, Gouveia M2, Fiorentino F1, Alarcão J1, Pascoal J3, Costa J4, Borges M1
1Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 2Católica Lisbon School of Business and Economics, Lisbon, Portugal, 3Centro Hospitalar Lisboa Central, Lisbon, Portugal, Lisbon, Portugal, 4Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

PMH37
A37
A PATIENT SURVEY REGARDING RISK OF OPIOID ABUSE: RESULTS OF A PILOT STUDY
Raisch DW1, Gu NY2, Anderson JR1, Chen C1, Al Moiakel K1, Patton RD1, Georgopoulos LL1
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2St. Jude Medical, Sylmar, CA, USA

PMH38
A38
EFFECTS OF MEDICAL MARIJUANA LEGALIZATION ON MARIJUANA USE AMONG ADOLESCENTS AND ADULTS IN THE UNITED STATES
Wong S, Lin H
Indiana University, Bloomington, IN, USA

PMH39
B1
COMPARATIVE ANALYSIS OF CONSUMPTION OF ANTIPSYCHOTIC DRUGS FOR TREATING SCHIZOPHRENIA IN HOSPITALS IN RUSSIAN FEDERATION
Vaskova L, Musina N, Tiapkina M
Sechenov First Moscow State Medical University, Moscow, Russia

PMH40
B2
PRESCRIBING PATTERNS OF PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Truter I
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa

PMH41
B3
DISCHARGE PRESCRIPTION PATTERNS OF ANTIPSYCHOTICS IN PATIENTS WITH MENTAL ILLNESS HOSPITALIZED COMPULSORILY BY PREFECTURAL GOVERNORS
Inagaki A1, Seto H2, Shimada T3, Oguchi Y4, Endoh Y5, Koizumi N6, Yoshizumi A7
1Aoyama Gakuin University, Shibuya, Tokyo, Japan, 2Nagasaki Medical Center of Psychiatry, Ohmura, Nagasaki, Japan, 3Tochigi Prefectural Okamotodai Hospital, Utsunomiya, Tochigi, Japan, 4Japan Agency for Medical Research and Development, Chiyoda, Tokyo, Japan, 5Seiwa Hospital, Institute of Neuropsychiatry, Shinjuku, Tokyo, Japan, 6Nagano Prefectural Mental Health and Welfare Center, Nagano, Nagano, Japan, 7Yahata Kosei Hospital, Kitakyusyu, Fukuoka, Japan

PMH42
B4
THE PREVALENCE OF ATYPICAL ANTIPSYCHOTIC MEDICATION USE FOR PEDIATRIC PSYCHOSIS IN KOREA
Lee H, Kang H
College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea

PMH43
B5
THREE-MONTHLY LONG-ACTING ANTIPSYCHOTIC THERAPY RESULTS IN A BETTER TREATMENT CONTINUITY COMPARED TO A ONE-MONTHLY OR BI-WEEKLY TREATMENT IN SCHIZOPHRENIA
Tedouri F1, Denee TR2, Malfait B3, Van Impe K2
1Janssen Pharmaceutica NV, Beerse, Belgium, 2Janssen-Cilag BV, Tilburg, The Netherlands, 3Janssen-Cilag NV, Beerse, Belgium

PMH44
B6
SLEEPING PILLS USE AMONG ADULTS IN ISRAEL
Cohen A, Porath A, Stein - Reisner O
Maccabi Healthcare Services, Tel-Aviv, Israel

PMH45
B7
EXAMINING THE RELATIONSHIP BETWEEN SUICIDAL IDEATION, DEPRESSION AND SELECTED CHRONIC DISEASES USING THE NHANES DATASET
Shalhoub H1, Rafael Albertorio-Díaz J2, Reaney M3
1Evidera & Bentley University, LYNN, MA, USA, 2Center for Disease Control and Prevention, Hyattsville, MD, USA, 3ERT, Peterborough, UK

PMH46
B8
MENTAL HEALTH - COSTS AND TREATMENT PENETRATION ACROSS EUROPE
Skoupa J, Hambalek J
Czech Health-Economy Society, Prague, Czech Republic

PMH47
B9
TREATMENT INDICATIONS FOR ANTIDEPRESSANTS PRESCRIBED IN PRIMARY CARE IN FRANCE, 2006-2015
Schwalm M, Miotti H, Hellard C, Bounit L, Trehony J, Jouaville SL
IMS HEALTH, Boulogne Billancourt, France

PMH48
B10
FEASIBILITY, RELIABILITY AND VALIDITY OF THE DECISION TOOL UNIPOLAR DEPRESSION (DTUD) IN IDENTIFYING PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN NEED OF HIGHLY SPECIALIZED CARE
van Krugten FC1, Kaddouri M1, Goorden M1, van Balkom AJ2, Ruhé HG3, van Schaik DJ2, van Oppen P2, Hakkaart-van Roijen L1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands, 3University Medical Centre Groningen, Groningen, The Netherlands

PMH49
B11
EARLY INDICATORS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN NEED OF HIGHLY SPECIALIZED CARE: A SYSTEMATIC REVIEW
van Krugten FC1, Kaddouri M1, Goorden M1, van Balkom AJ2, Bockting CL3, Peeters FP4, Hakkaart-van Roijen L1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands, 3Utrecht University, Utrecht, The Netherlands, 4Maastricht University, Maastricht, The Netherlands

PMH50
B12
RETROSPECTIVE DATABASE STUDY DESCRIBING PATIENT CHARACTERISTICS AND RESOURCE USE IN SWEDISH PATIENTS RECEIVING SECOND GENERATION LONG ACTING INJECTION ANTIPSYCHOTICS
Hernlund E1, Landfeldt E1, Lombard LA2, Tockhorn-Heidenreich A2, Bushe C2, Porsdal V3, Eriksson J1, Berg J1
1Mapi Group, Stockholm, Sweden, 2Eli Lilly, Windlesham, UK, 3Eli Lilly, Herlev, Denmark

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.